Saturday 7 November 2026 Export IMTX’s income statement to Excel — free account

Immatics N.V.

IMTX Healthcare Biotechnology

Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024.

Revenue: +97.7%
EPS: +19.7%
Free cash flow: −44.4%

Quarter to June 2026, against a year earlier

Insider buying

6.34 0.16 +2.59%

Follow IMTX

Alert me

Market cap: $924.8M
P/E: 0.0×
Fwd P/E: −3.5×
Dividend yield: —
F-score: 3/9
Altman Z: 6.75
Beneish M: −1.36
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 7.50

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	1	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.56%

Capital & Financial Ratios $m

Size

Market Cap 924.75

Revenue ttm 49.20

Net income ttm (237.04)

Free cash flow ttm (240.08)

Net debt Q (270.28)

Valuation

P/E 0.00

Forward P/E (3.46)

Price / sales 17.61

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.87

Financial health

Current ratio Q 7.54

Debt / equity Q 0.00

Interest coverage Q (184.64)

Growth

Revenue growth Q +97.71%

Operating income growth Q −29.56%

EPS, this year −12.02%

EPS, next year A −2.56%

Revenue, next year A −16.97%

EPS, past 5 yrs —

EPS, next 5 yrs A −0.15%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 69.56%

10-year low 10-year high

P/B against its own 10 years 11.02%

10-year low 10-year high

EV/Sales against its own 10 years 63.36%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	236	256	391	270
Receivables	4	6	7	7
Inventory	—	—	—	—
Other	245	419	172	222
	486	681	570	499

	2023	2024	2025	Q'26
Payables	27	22	21	39
ST’ Debt	—	—	—	—
Other	31	9	6	13
	169	74	49	66

Compound Annual Growth %

	10y	5y	3y
Sales	—	11.81%	(33.06%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	39.34%	34.60%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate −0.43 Actual −0.53

−0.56 −0.50 −0.43 −0.37 −0.31

Sep 2025 Beat +0.01

Dec 2025 Beat +0.14

Mar 2026 Miss −0.08

Jun 2026 Miss −0.10

Sep 2026 — Nov 16

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Sep 2025	−0.50	−0.49	Beat by 0.01
Dec 2025	−0.48	−0.34	Beat by 0.14
Mar 2026	−0.42	−0.50	Miss by 0.08
Jun 2026	−0.43	−0.53	Miss by 0.10
Sep 2026	−0.49	—	Reports 16 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.50)	(0.53)	—	—	—
’25	(0.35)	(0.66)	(0.49)	(0.34)	(1.82)
’24	(0.03)	(0.18)	(0.09)	0.48	0.15
’23	(0.28)	(0.35)	(0.35)	(0.32)	(1.30)
’22	1.52	(0.23)	(0.32)	(0.23)	0.58
’21	(0.41)	(0.46)	(0.51)	(0.30)	(1.75)
’20	(0.18)	(20.19)	(3.30)	18.88	(5.02)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	11	—	—	—
’25	20	5	6	24	55
’24	33	20	56	60	169
’23	11	24	6	17	58
’22	115	18	15	33	182
’21	9	6	8	18	41
’20	8	8	9	14	31

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(49)	(70)	—	—	—
’25	(36)	(47)	(55)	(62)	(200)
’24	(35)	(35)	(39)	(62)	(171)
’23	(25)	(8)	(33)	86	20
’22	122	52	(42)	(27)	105
’21	(20)	(24)	(21)	(32)	(97)
’20	0	(13)	(57)	(16)	(86)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(50)	(71)	—	—	—
’25	(39)	(49)	(56)	(63)	(208)
’24	(45)	(38)	(42)	(63)	(189)
’23	(30)	(19)	(40)	76	(14)
’22	121	51	(43)	(30)	99
’21	(21)	(26)	(23)	(34)	(103)
’20	0	(18)	(59)	(16)	(93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	4	18	31	41	182	58	169	55	49		+46.5%	45	39	117	+29.1%
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Immatics N.V.’s next three years, line by line Analysts expect revenue to grow 29.1% a year to 2028 — slower than the 46.5% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	(32)	(32)	(230)	(110)	44	(105)	23	(225)	(241)		+31.9%
	EBT margin, %	—	—	(858.22)	(176.09)	(734.70)	(268.49)	24.32	(179.63)	13.70	(411.13)	(490.01)		+447.1 pt
	Net income	—	0	(32)	(32)	(230)	(110)	40	(105)	16	(222)	(237)		n/m
Per share, $
Per share, $	Revenue	—	—	0.11	0.56	0.65	0.65	2.71	0.73	1.59	0.45	0.36		+21.5%
	Earnings	—	—	(0.98)	(0.98)	(5.02)	(1.75)	0.59	(1.30)	0.15	(1.82)	(1.86)		+9.3%
	Cash flow	—	—	0.63	2.14	(1.78)	(1.54)	1.57	0.24	(1.62)	(1.63)	(1.73)		n/m
	Capex	—	—	(0.01)	(0.06)	(0.16)	(0.11)	(0.10)	(0.41)	(0.17)	(0.06)	(0.03)		+26.0%
	Free cash flow	—	—	0.61	2.08	(1.94)	(1.64)	1.47	(0.17)	(1.79)	(1.70)	(1.76)		n/m
	Book value	—	—	0.15	(1.23)	2.17	0.45	3.34	3.02	5.88	4.48	3.40		+62.3%
	Shares, m	—	—	33	33	48	63	67	81	106	122	129		+20.5%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	11.43	0.00	39.50	0.00	0.00		6.4
	P/S	—	—	0.00	0.00	13.28	20.56	3.16	14.78	4.46	23.53	17.61		10.0
	P/B	—	—	6.13	0.00	4.97	29.70	2.57	3.54	1.21	2.35	1.87		6.3
	EV/Sales	—	—	0.00	0.00	7.96	16.73	2.30	10.73	2.94	16.36	12.12		7.1
	EV/FCF	—	—	0.00	3.39	(3.26)	(6.65)	4.24	(46.06)	(2.62)	(4.30)	(2.48)		(6.9)
Cash, $m
Cash, $m	Operating cash flow	—	—	21	71	(86)	(97)	105	20	(171)	(200)	(236)		n/m
	Capex	—	—	0	(2)	(8)	(7)	(6)	(33)	(18)	(8)	(4)		+51.9%
	Free cash flow	—	—	20	69	(93)	(103)	99	(14)	(189)	(208)	(240)		n/m
Balance, $m
Balance, $m	Working capital	—	—	1	55	178	68	285	317	608	522	433		+134.8%
	Net debt	—	—	(1)	(103)	(208)	(157)	(156)	(236)	(256)	(391)	(270)		+128.6%
	Shareholders’ equity	—	—	5	(41)	104	28	225	244	622	548	465		+95.6%
Returns, %
Returns, %	ROA	—	—	(43.13)	(22.54)	(123.97)	(47.88)	12.42	(21.39)	2.52	(31.99)	(39.83)		+11.1 pt
	ROIC	—	—	(565.68)	0.00	0.00	0.00	28.96	(961.55)	(7.14)	(82.33)	(84.83)		+483.3 pt
	ROE	—	—	106.81	176.20	(760.26)	(166.40)	31.24	(44.84)	3.80	(38.00)	(48.53)		(144.8) pt
People
People	Employees	—	—	2	2	198	255	293	343	423	407	—		+113.7%
	Revenue/emp, $m	—	—	1.89	9.22	0.16	0.16	0.62	0.17	0.40	0.13	—		(31.4%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
JANX Janux Therapeutics, Inc.	$981.9M	— (loss-making)	— (loss-making)	0.00%	n/m	−94.49% (below 0%: shrinking)	100.00%	(336.51%)	Compare
IMTX Immatics N.V.	$924.8M	— (loss-making)	— (loss-making)	+97.71% (above 0%: growing)	n/m	−44.41% (below 0%: shrinking)	100.00%	(734.95%)
MLTX MoonLake Immunotherapeutics	$919.2M	— (loss-making)	—	—	n/m	−1.89% (below 0%: shrinking)	0.00%	0.00%	Compare
ODTX Odyssey Therapeutics, Inc.	$907.3M	— (loss-making)	—	—	n/m	—	100.00%	0.00%	Compare
SVRA Savara Inc.	$899.9M	— (loss-making)	— (loss-making)	—	n/m	−14.05% (below 0%: shrinking)	0.00%	0.00%	Compare
JBIO Jade Biosciences, Inc.	$896.7M	— (loss-making)	—	—	n/m	−115.11% (below 0%: shrinking)	0.00%	0.00%	Compare
CTY City Therapeutics, Inc	$882.9M	—	—	—	—	—	—	—	Compare
ORIC Oric Pharmaceuticals, Inc.	$880.0M	— (loss-making)	—	—	n/m	−3.42% (below 0%: shrinking)	0.00%	0.00%	Compare
GLUE Monte Rosa Therapeutics, Inc.	$874.5M	— (loss-making)	— (loss-making)	+325.80% (above 0%: growing)	n/m	−142.63% (below 0%: shrinking)	100.00%	(3.57%)	Compare
Median of peers	$898.3M	—	—	—	—	−54.27%	0.00%	0.00%

All 621 Biotechnology stocks →

Immatics N.V. (IMTX) Latest News

31 Oct

Impact 3 · 8:21 PM · Simply Wall St.

Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In Focus

28 Oct

Impact 4 · 9:09 PM · Simply Wall St.

Immatics (IMTX) Stock Looks Stretched As PRAME Trial Data Impresses

24 Oct

Impact 4 · 11:20 PM · Simply Wall St.

Should Updated Trial Results Require Action From Immatics (IMTX) Investors?

Impact 4 · 2:30 AM · GlobeNewswire

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

25 Aug

Impact 3 · 7:00 AM

Immatics Announces $150 Million Underwritten Offering

18 Aug

Impact 4 · 7:00 AM

Immatics Announces Second Quarter 2026 Financial Results and Business Update

1 Jun

Impact 4 · 8:00 AM · GlobeNewswire

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

31 May

Impact 4 · 9:00 AM · GlobeNewswire

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

30 May

Impact 4 · 8:00 AM · GlobeNewswire

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

15 May

Impact 3 · 6:59 AM · Simply Wall St.

Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results

12 May

Impact 3 · 8:25 AM · Zacks

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Impact 3 · 7:00 AM · GlobeNewswire

Immatics Announces First Quarter 2026 Financial Results and Business Update

21 Apr

Impact 4 · 10:26 AM

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

17 Apr

Impact 4 · 3:00 PM · GlobeNewswire

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

15 Mar

Impact 4 · 4:06 PM · Simply Wall St.

Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside

13 Mar

Impact 4 · 2:31 PM · Insider Monkey

Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate

5 Mar

Impact 4 · 7:00 AM · GlobeNewswire

Immatics Announces Full Year 2025 Financial Results and Business Update

Impact 3 · 7:30 AM · Associated Press Finance

Immatics: Q4 Earnings Snapshot

15 Jan

Impact 3 · 8:03 AM · Simply Wall St.Simply Wall St.

Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)

11 Dec

Impact 4 · 7:00 AM · GlobeNewswireMT NewswiresSimply Wall St.Motley FoolGuruFocus.comMotley FoolMotley FoolMotley Fool

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

5 Dec

Impact 4 · 6:00 AM · GlobeNewswireMT NewswiresMT NewswiresMT NewswiresSimply Wall St.Simply Wall St.Associated Press Finance

Immatics Announces $125 Million Underwritten Offering

Impact 3 · 7:19 PM · Simply Wall St.

Immatics (NasdaqCM:IMTX) Valuation Check After Follow-On Share Offering Announcement

18 Nov

Impact 4 · 9:40 AM · Zacks

Company News for Nov 18, 2025

Impact 4 · 2:07 AM · Simply Wall St.

Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention?

17 Nov

Impact 4 · 7:00 AM · GlobeNewswire

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Impact 3 · 8:15 AM

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Impact 3 · 7:13 AM · Associated Press Finance

Immatics: Q3 Earnings Snapshot

12 Nov

Impact 4 · 7:00 AM

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

11 Nov

Impact 3 · 8:13 AM · Simply Wall St.Simply Wall St.Simply Wall St.MT NewswiresSimply Wall St.

Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum

27 Oct

Impact 3 · 7:00 AM · GlobeNewswire

Immatics Appoints Amie Krause as Chief People Officer

Immatics N.V.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Immatics N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Immatics N.V. (IMTX) Latest News

31 Oct

28 Oct

24 Oct

25 Aug

18 Aug

1 Jun

31 May

30 May

15 May

12 May

21 Apr

17 Apr

15 Mar

13 Mar

5 Mar

15 Jan

11 Dec

5 Dec

18 Nov

17 Nov

12 Nov

11 Nov

27 Oct

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Immatics N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Immatics N.V. (IMTX) Latest News

31 Oct

28 Oct

24 Oct

25 Aug

18 Aug

1 Jun

31 May

30 May

15 May

12 May

21 Apr

17 Apr

15 Mar

13 Mar

5 Mar

15 Jan

11 Dec

5 Dec

18 Nov

17 Nov

12 Nov

11 Nov

27 Oct

Stockrow Weekly